Enhancing the therapeutic efficacy of adenovirus in combination with biomaterials

Biomaterials

Volumn 33, Issue 6, 2012, Pages 1838-1850

  Kim, Jaesung ^a   Kim, Pyung Hwan ^a   Kim, Sung Wan ^a,b   Yun, Chae Ok ^b  

^a UNIVERSITY OF UTAH   (United States)

^b Hanyang University   (South Korea)

Author keywords

Active targeting; Adenovirus; Biomaterials; Cancer gene therapy; Passive targeting

Indexed keywords

ACTIVE TARGETING; ADENOVIRUS; CANCER GENE THERAPY; CANCER THERAPY; CIRCULATION TIME; ENHANCED PERMEABILITY AND RETENTION EFFECTS; GROWTH FACTOR; IMMUNE RESPONSE; IN-VIVO; LIVER TOXICITY; PASSIVE TARGETING; PHYSICAL MODIFICATIONS; TARGET CELLS; THERAPEUTIC EFFICACY; VECTOR SYSTEMS;

BIOLOGICAL MATERIALS; BIOMATERIALS; CHEMICAL MODIFICATION; DISEASES; GENES; GLYCOLS; LIGANDS; PEPTIDES; PLASTIC COATINGS; POLYETHYLENE GLYCOLS; TUMORS; VECTORS;

FUNCTIONAL POLYMERS;

ADENOVIRUS VECTOR; ALGINIC ACID; ARGINYLGLYCYLASPARTIC ACID; AVIDIN; BIOMATERIAL; BIOTIN; CETUXIMAB; CHITOSAN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FOLIC ACID; MACROGOL; POLY[N (2 HYDROXYPROPYL)METHACRYLAMIDE]; POLYETHYLENEIMINE; POLYLYSINE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; TRASTUZUMAB; VASCULOTROPIN; VERY LATE ACTIVATION ANTIGEN 6;

ADAPTIVE IMMUNITY; BREAST CANCER; CANCER GENE THERAPY; CHEMICAL ENGINEERING; CHEMICAL MODIFICATION; CIRCULATION TIME; COLORECTAL CANCER; CROSS LINKING; DRUG ACCUMULATION; DRUG EFFICACY; GENE EXPRESSION; GENE TARGETING; GENETIC ENGINEERING; GENETIC TRANSDUCTION; HEAD AND NECK CANCER; HUMAN; IN VIVO STUDY; LIPOSOMAL DELIVERY; LIVER TOXICITY; MICROENCAPSULATION; NONHODGKIN LYMPHOMA; OVARY CANCER; OVARY CARCINOMA; PAPILLARY CARCINOMA; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; TARGET CELL; TRANSGENE; TUMOR LOCALIZATION; UTERUS CARCINOMA;

ADENOVIRIDAE; ANIMALS; BIOCOMPATIBLE MATERIALS; CHITOSAN; GENE THERAPY; HUMANS; LIGANDS; LIPOSOMES; METHACRYLATES; MICE; NEOPLASMS; OLIGOPEPTIDES; PEPTIDES; POLYETHYLENE GLYCOLS; POLYETHYLENEIMINE; POLYLYSINE; POLYMERS;

ADENOVIRIDAE;

EID: 83555178348     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.11.020     Document Type: Review

References (162)

1. Rowe W.P., Huebner R.J., Gilmore L.K., Parrott R.H., Ward T.G. Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proc Soc Exp Biol Med 1953, 84(3):570-573.
2. Huebner R.J., Rowe W.P., Schatten W.E., Smith R.R., Thomas L.B. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer 1956, 9(6):1211-1218.
3. Kelly E., Russell S.J. History of oncolytic viruses: genesis to genetic engineering. Mol Ther 2007, 15(4):651-659.
4. Georgiades J., Zielinski T., Cicholska A., Jordan E. Research on the oncolytic effect of APC viruses in cancer of the cervix uteri; preliminary report. Biul Inst Med Morsk Gdansk 1959, 10:49-57.
5. Zielinski T., Jordan E. Remote results of clinical observation of the oncolytic action of adenoviruses on cervix cancer. Nowotwory 1969, 19(3):217-221.
6. Imperiale M.J., Kochanek S. Adenovirus vectors: biology, design, and production. Curr Top Microbiol Immunol 2004, 273:335-357.
7. Kanerva A., Hemminki A. Modified adenoviruses for cancer gene therapy. Int J Cancer 2004, 110(4):475-480.
8. Bischoff J.R., Kirn D.H., Williams A., Heise C., Horn S., Muna M., et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996, 274(5286):373-376.
9. Jounaidi Y., Doloff J.C., Waxman D.J. Conditionally replicating adenoviruses for cancer treatment. Curr Cancer Drug Targets 2007, 7(3):285-301.
10. Pesonen S., Kangasniemi L., Hemminki A. Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data. Mol Pharm 2011, 8(1):12-28.
11. Kim J., Cho J.Y., Kim J.H., Jung K.C., Yun C.O. Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy. Cancer Gene Ther 2002, 9(9):725-736.
12. Kim J., Kim J.H., Choi K.J., Kim P.H., Yun C.O. E1A- and E1B-Double mutant replicating adenovirus elicits enhanced oncolytic and antitumor effects. Hum Gene Ther 2007, 18(9):773-786.
13. DeWeese T.L., van der Poel H., Li S., Mikhak B., Drew R., Goemann M., et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 2001, 61(20):7464-7472.
14. Kim J., Lee B., Kim J.S., Yun C.O., Kim J.H., Lee Y.J., et al. Antitumoral effects of recombinant adenovirus YKL-1001, conditionally replicating in alpha-fetoprotein-producing human liver cancer cells. Cancer Lett 2002, 180(1):23-32.
15. Li Y., Chen Y., Dilley J., Arroyo T., Ko D., Working P., et al. Carcinoembryonic antigen-producing cell-specific oncolytic adenovirus, OV798, for colorectal cancer therapy. Mol Cancer Ther 2003, 2(10):1003-1009.
16. Kurihara T., Brough D.E., Kovesdi I., Kufe D.W. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest 2000, 106(6):763-771.
17. Kim E., Kim J.H., Shin H.Y., Lee H., Yang J.M., Kim J., et al. Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. Hum Gene Ther 2003, 14(15):1415-1428.
18. Kwon O.J., Kim P.H., Huyn S., Wu L., Kim M., Yun C.O. A hypoxia- and {alpha}-fetoprotein-dependent oncolytic adenovirus exhibits specific killing of hepatocellular carcinomas. Clin Cancer Res 2011, 16(24):6071-6082.
19. Alemany R., Balague C., Curiel D.T. Replicative adenoviruses for cancer therapy. Nat Biotechnol 2000, 18(7):723-727.
20. Zhang W.W., Alemany R., Wang J., Koch P.E., Ordonez N.G., Roth J.A. Safety evaluation of Ad5CMV-p53 in vitro and in vivo. Hum Gene Ther 1995, 6(2):155-164.
21. Shewach D.S., Zerbe L.K., Hughes T.L., Roessler B.J., Breakefield X.O., Davidson B.L. Enhanced cytotoxicity of antiviral drugs mediated by adenovirus directed transfer of the herpes simplex virus thymidine kinase gene in rat glioma cells. Cancer Gene Ther 1994, 1(2):107-112.
22. Hirschowitz E.A., Ohwada A., Pascal W.R., Russi T.J., Crystal R.G. In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine. Hum Gene Ther 1995, 6(8):1055-1063.
23. Griffith T.S., Anderson R.D., Davidson B.L., Williams R.D., Ratliff T.L. Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J Immunol 2000, 165(5):2886-2894.
24. Choi K.J., Kim J.H., Lee Y.S., Kim J., Suh B.S., Kim H., et al. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect. Gene Ther 2006, 13(13):1010-1020.
25. Lee Y.S., Kim J.H., Choi K.J., Choi I.K., Kim H., Cho S., et al. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model. Clin Cancer Res 2006, 12(19):5859-5868.
26. Yoo J.Y., Kim J.H., Kwon Y.G., Kim E.C., Kim N.K., Choi H.J., et al. VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth. Mol Ther 2007, 15(2):295-302.
27. Yoo J.Y., Kim J.H., Kim J., Huang J.H., Zhang S.N., Kang Y.A., et al. Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: effects on antiangiogenesis and tumor growth inhibition. Gene Ther 2008, 15(9):635-651.
28. Yun C.O., Kim E., Koo T., Kim H., Lee Y.S., Kim J.H. ADP-overexpressing adenovirus elicits enhanced cytopathic effect by induction of apoptosis. Cancer Gene Ther 2005, 12(1):61-71.
29. Kim J.H., Lee Y.S., Kim H., Huang J.H., Yoon A.R., Yun C.O. Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy. J Natl Cancer Inst 2006, 98(20):1482-1493.
30. Choi I.K., Lee Y.S., Yoo J.Y., Yoon A.R., Kim H., Kim D.S., et al. Effect of decorin on overcoming the extracellular matrix barrier for oncolytic virotherapy. Gene Ther 2010, 17(2):190-201.
31. Alemany R., Suzuki K., Curiel D.T. Blood clearance rates of adenovirus type 5 in mice. J Gen Virol 2000, 81(Pt 11):2605-2609.
32. Nemunaitis J., O'Brien J. Head and neck cancer: gene therapy approaches. Part II: genes delivered. Expert Opin Biol Ther 2002, 2(3):311-324.
33. Muruve D.A., Barnes M.J., Stillman I.E., Libermann T.A. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum Gene Ther 1999, 10(6):965-976.
34. Zhang Y., Chirmule N., Gao G.P., Qian R., Croyle M., Joshi B., et al. Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol Ther 2001, 3(5 Pt 1):697-707.
35. Liu Q., Zaiss A.K., Colarusso P., Patel K., Haljan G., Wickham T.J., et al. The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors. Hum Gene Ther 2003, 14(7):627-643.
36. Kiang A., Hartman Z.C., Everett R.S., Serra D., Jiang H., Frank M.M., et al. Multiple innate inflammatory responses induced after systemic adenovirus vector delivery depend on a functional complement system. Mol Ther 2006, 14(4):588-598.
37. Molnar-Kimber K.L., Sterman D.H., Chang M., Kang E.H., ElBash M., Lanuti M., et al. Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Hum Gene Ther 1998, 9(14):2121-2133.
38. Sumida S.M., Truitt D.M., Lemckert A.A., Vogels R., Custers J.H., Addo M.M., et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol 2005, 174(11):7179-7185.
39. Oberholzer C., Oberholzer A., Tschoeke S.K., Minter R.M., Bahjat F.R., LaFace D., et al. Influence of recombinant adenovirus on liver injury in endotoxicosis and its modulation by IL-10 expression. J Endotoxin Res 2004, 10(6):393-401.
40. Seymour L.W. Passive tumor targeting of soluble macromolecules and drug conjugates. Crit Rev Ther Drug Carrier Syst 1992, 9(2):135-187.
41. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986, 46(12 Pt 1):6387-6392.
42. Kreppel F., Kochanek S. Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide. Mol Ther 2008, 16(1):16-29.
43. Fisher K.D., Seymour L.W. HPMA copolymers for masking and retargeting of therapeutic viruses. Adv Drug Deliv Rev 2010, 62(2):240-245.
44. Kang E., Yun C.O. Current advances in adenovirus nanocomplexes: more specificity and less immunogenicity. BMB Rep 2010, 43(12):781-788.
45. Jang J.H., Schaffer D.V., Shea L.D. Engineering biomaterial systems to enhance viral vector gene delivery. Mol Ther 2011, 19(8):1407-1415.
46. Gall J., Kass-Eisler A., Leinwand L., Falck-Pedersen E. Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes. J Virol 1996, 70(4):2116-2123.
47. Ophorst O.J., Kostense S., Goudsmit J., De Swart R.L., Verhaagh S., Zakhartchouk A., et al. An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity. Vaccine 2004, 22(23-24):3035-3044.
48. Mizuguchi H., Hayakawa T. Targeted adenovirus vectors. Hum Gene Ther 2004, 15(11):1034-1044.
49. O'Riordan C.R., Lachapelle A., Delgado C., Parkes V., Wadsworth S.C., Smith A.E., et al. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum Gene Ther 1999, 10(8):1349-1358.
50. Myhre S., Henning P., Granio O., Tylo A.S., Nygren P.A., Olofsson S., et al. Decreased immune reactivity towards a knobless, affibody-targeted adenovirus type 5 vector. Gene Ther 2007, 14(4):376-381.
51. Croyle M.A., Chirmule N., Zhang Y., Wilson J.M. PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. Hum Gene Ther 2002, 13(15):1887-1900.
52. Fisher K.D., Stallwood Y., Green N.K., Ulbrich K., Mautner V., Seymour L.W. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther 2001, 8(5):341-348.
53. Mok H., Palmer D.J., Ng P., Barry M.A. Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol Ther 2005, 11(1):66-79.
54. Wortmann A., Vohringer S., Engler T., Corjon S., Schirmbeck R., Reimann J., et al. Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies. Mol Ther 2008, 16(1):154-162.
55. Hofherr S.E., Shashkova E.V., Weaver E.A., Khare R., Barry M.A. Modification of adenoviral vectors with polyethylene glycol modulates in vivo tissue tropism and gene expression. Mol Ther 2008, 16(7):1276-1282.
56. Gao J.Q., Eto Y., Yoshioka Y., Sekiguchi F., Kurachi S., Morishige T., et al. Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration. J Control Release 2007, 122(1):102-110.
57. Yao X., Yoshioka Y., Morishige T., Eto Y., Watanabe H., Okada Y., et al. Systemic administration of a PEGylated adenovirus vector with a cancer-specific promoter is effective in a mouse model of metastasis. Gene Ther 2009, 16(12):1395-1404.
58. Weaver E.A., Barry M.A. Effects of shielding adenoviral vectors with polyethylene glycol on vector-specific and vaccine-mediated immune responses. Hum Gene Ther 2008, 19(12):1369-1382.
59. Braet F., Wisse E. Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review. Comp Hepatol 2002, 1(1):1.
60. Kreppel F., Gackowski J., Schmidt E., Kochanek S. Combined genetic and chemical capsid modifications enable flexible and efficient de- and retargeting of adenovirus vectors. Mol Ther 2005, 12(1):107-117.
61. Suzuki-Kouyama E., Katayama K., Sakurai F., Yamaguchi T., Kurachi S., Kawabata K., et al. Hexon-specific PEGylated adenovirus vectors utilizing avidin-biotin interaction. Biomaterials 2011, 32(6):1724-1730.
62. Green N.K., Herbert C.W., Hale S.J., Hale A.B., Mautner V., Harkins R., et al. Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. Gene Ther 2004, 11(16):1256-1263.
63. Fisher K.D., Green N.K., Hale A., Subr V., Ulbrich K., Seymour L.W. Passive tumour targeting of polymer-coated adenovirus for cancer gene therapy. J Drug Target 2007, 15(7-8):546-551.
64. Subr V., Kostka L., Selby-Milic T., Fisher K., Ulbrich K., Seymour L.W., et al. Coating of adenovirus type 5 with polymers containing quaternary amines prevents binding to blood components. J Control Release 2009, 135(2):152-158.
65. Karlin S., Brendel V. Charge configurations in viral proteins. Proc Natl Acad Sci U S A 1988, 85(24):9396-9400.
66. Boussif O., Lezoualc'h F., Zanta M.A., Mergny M.D., Scherman D., Demeneix B., et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci 1995, 92(16):7297-7301.
67. Baker A., Saltik M., Lehrmann H., Killisch I., Mautner V., Lamm G., et al. Polyethylenimine (PEI) is a simple, inexpensive and effective reagent for condensing and linking plasmid DNA to adenovirus for gene delivery. Gene Ther 1997, 4(8):773-782.
68. Meunier-Durmort C., Grimal H., Sachs L.M., Demeneix B.A., Forest C. Adenovirus enhancement of polyethylenimine-mediated transfer of regulated genes in differentiated cells. Gene Ther 1997, 4(8):808-814.
69. Fischer D., Bieber T., Li Y., Elsasser H.P., Kissel T. A novel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine: effect of molecular weight on transfection efficiency and cytotoxicity. Pharm Res 1999, 16(8):1273-1279.
70. Kunath K., von Harpe A., Fischer D., Petersen H., Bickel U., Voigt K., et al. Low-molecular-weight polyethylenimine as a non-viral vector for DNA delivery: comparison of physicochemical properties, transfection efficiency and in vivo distribution with high-molecular-weight polyethylenimine. J Control Release 2003, 89(1):113-125.
71. Han J., Zhao D., Zhong Z., Zhang Z., Gong T., Sun X. Combination of adenovirus and cross-linked low molecular weight PEI improves efficiency of gene transduction. Nanotechnology 2010, 21(10):105106.
72. Wu G.Y., Wu C.H. Receptor-mediated in vitro gene transformation by a soluble DNA carrier system. J Biol Chem 1987, 262(10):4429-4432.
73. Park T.G., Jeong J.H., Kim S.W. Current status of polymeric gene delivery systems. Adv Drug Deliv Rev 2006, 58(4):467-486.
74. Fasbender A., Zabner J., Chillon M., Moninger T.O., Puga A.P., Davidson B.L., et al. Complexes of adenovirus with polycationic polymers and cationic lipids increase the efficiency of gene transfer in vitro and in vivo. J Biol Chem 1997, 272(10):6479-6489.
75. Ward C.M., Read M.L., Seymour L.W. Systemic circulation of poly(L-lysine)/DNA vectors is influenced by polycation molecular weight and type of DNA: differential circulation in mice and rats and the implications for human gene therapy. Blood 2001, 97(8):2221-2229.
76. Caplen N.J., Alton E.W., Middleton P.G., Dorin J.R., Stevenson B.J., Gao X., et al. Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nat Med 1995, 1(1):39-46.
77. Park J.W., Mok H., Park T.G. Physical adsorption of PEG grafted and blocked poly-L-lysine copolymers on adenovirus surface for enhanced gene transduction. J Control Release 2010, 142(2):238-244.
78. Chillon M., Lee J.H., Fasbender A., Welsh M.J. Adenovirus complexed with polyethylene glycol and cationic lipid is shielded from neutralizing antibodies in vitro. Gene Ther 1998, 5(7):995-1002.
79. Singh R., Tian B., Kostarelos K. Artificial envelopment of nonenveloped viruses: enhancing adenovirus tumor targeting in vivo. Faseb J 2008, 22(9):3389-3402.
80. Kawamata Y., Nagayama Y., Nakao K., Mizuguchi H., Hayakawa T., Sato T., et al. Receptor-independent augmentation of adenovirus-mediated gene transfer with chitosan in vitro. Biomaterials 2002, 23(23):4573-4579.
81. Park Y., Kang E., Kwon O.J., Hwang T., Park H., Lee J.M., et al. Ionically crosslinked Ad/chitosan nanocomplexes processed by electrospinning for targeted cancer gene therapy. J Control Release 2010, 148:75.
82. Chollet P., Favrot M.C., Hurbin A., Coll J.L. Side-effects of a systemic injection of linear polyethylenimine-DNA complexes. J Gene Med 2002, 4(1):84-91.
83. Boeckle S., Wagner E. Optimizing targeted gene delivery: chemical modification of viral vectors and synthesis of artificial virus vector systems. Aaps J 2006, 8(4):E731-E742.
84. Sonawane N.D., Szoka F.C., Verkman A.S. Chloride accumulation and swelling in endosomes enhances DNA transfer by polyamine-DNA polyplexes. J Biol Chem 2003, 278(45):44826-44831.
85. Ou M., Wang X.L., Xu R., Chang C.W., Bull D.A., Kim S.W. Novel biodegradable poly(disulfide amine)s for gene delivery with high efficiency and low cytotoxicity. Bioconjug Chem 2008, 19(3):626-633.
86. Jere D., Arote R., Jiang H.L., Kim Y.K., Cho M.H., Cho C.S. Bioreducible polymers for efficient gene and siRNA delivery. Biomed Mater 2009, 4(2):025020.
87. Yu H., Russ V., Wagner E. Influence of the molecular weight of bioreducible oligoethylenimine conjugates on the polyplex transfection properties. Aaps J 2009, 11(3):445-455.
88. Kim T.I., Kim S.W. Bioreducible polymers for gene delivery. React Funct Polym 2011, 71(3):344-349.
89. Kim T.I., Ou M., Lee M., Kim S.W. Arginine-grafted bioreducible poly(disulfide amine) for gene delivery systems. Biomaterials 2009, 30(4):658-664.
90. Kim P.H., Kim T.I., Yockman J.W., Kim S.W., Yun C.O. The effect of surface modification of adenovirus with an arginine-grafted bioreducible polymer on transduction efficiency and immunogenicity in cancer gene therapy. Biomaterials 2010, 31(7):1865-1874.
91. Kim P.H., Kim J., Kim T.I., Nam H.Y., Yockman J.W., Kim M., et al. Bioreducible polymer-conjugated oncolytic adenovirus for hepatoma-specific therapy via systemic administration. Biomaterials 2011.
92. Kim J., Nam H.Y., Kim T.I., Kim P.H., Ryu J., Yun C.O., et al. Active targeting of RGD-conjugated bioreducible polymer for delivery of oncolytic adenovirus expressing shRNA against IL-8 mRNA. Biomaterials 2011, 32(22):5158-5166.
93. Aggarwal N., HogenEsch H., Guo P., North A., Suckow M., Mittal S.K. Biodegradable alginate microspheres as a delivery system for naked DNA. Can J Vet Res 1999, 63(2):148-152.
94. Bowersock T.L., HogenEsch H., Suckow M., Guimond P., Martin S., Borie D., et al. Oral vaccination of animals with antigens encapsulated in alginate microspheres. Vaccine 1999, 17(13-14):1804-1811.
95. Anderson M.G., Miller J.D. Therapeutic effects of leuprorelin microspheres on endometriosis and uterine leiomyomata. Adv Drug Deliv Rev 1997, 28(1):139-155.
96. Panyam J., Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 2003, 55(3):329-347.
97. Bangari D.S., Mittal S.K. Current strategies and future directions for eluding adenoviral vector immunity. Curr Gene Ther 2006, 6(2):215-226.
98. Sailaja G., HogenEsch H., North A., Hays J., Mittal S.K. Encapsulation of recombinant adenovirus into alginate microspheres circumvents vector-specific immune response. Gene Ther 2002, 9(24):1722-1729.
99. Kim P.H., Kang E., Choi J.W., Yun T.J., Park H.K., Kim J.H., et al. Sustained delivery of oncolytic adenovirus in alginate gel for local tumor virotheraphy. J Control Release 2010, 148(1):e100-e101.
100. Mok H., Park J.W., Park T.G. Microencapsulation of PEGylated adenovirus within PLGA microspheres for enhanced stability and gene transfection efficiency. Pharm Res 2007, 24(12):2263-2269.
101. Di Paolo N.C., Shayakhmetov D.M. Adenovirus de-targeting from the liver. Curr Opin Mol Ther 2009, 11(5):523-531.
102. Zaiss A.K., Machado H.B., Herschman H.R. The influence of innate and pre-existing immunity on adenovirus therapy. J Cell Biochem 2009, 108(4):778-790.
103. Eto Y., Yoshioka Y., Mukai Y., Okada N., Nakagawa S. Development of PEGylated adenovirus vector with targeting ligand. Int J Pharm 2008, 354(1-2):3-8.
104. Ruoslahti E. Vascular zip codes in angiogenesis and metastasis. Biochem Soc Trans 2004, 32(Pt3):397-402.
105. Laakkonen P., Porkka K., Hoffman J.A., Ruoslahti E. A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat Med 2002, 8(7):751-755.
106. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407(6801):249-257.
107. Paleolog E.M. Angiogenesis in rheumatoid arthritis. Arthritis Res 2002, 4(Suppl. 3):S81-S90.
108. Brooks P.C., Clark R.A., Cheresh D.A. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994, 264(5158):569-571.
109. Luo J., Paranya G., Bischoff J. Noninflammatory expression of E-selectin is regulated by cell growth. Blood 1999, 93(11):3785-3791.
110. Veikkola T., Karkkainen M., Claesson-Welsh L., Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 2000, 60(2):203-212.
111. Koivunen E., Wang B., Ruoslahti E. Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Biotechnol (N Y) 1995, 13(3):265-270.
112. Suh W., Han S.O., Yu L., Kim S.W. An angiogenic, endothelial-cell-targeted polymeric gene carrier. Mol Ther 2002, 6(5):664-672.
113. Kim W.J., Yockman J.W., Lee M., Jeong J.H., Kim Y.H., Kim S.W. Soluble Flt-1 gene delivery using PEI-g-PEG-RGD conjugate for anti-angiogenesis. J Control Release 2005, 106(1-2):224-234.
114. Eto Y., Gao J.Q., Sekiguchi F., Kurachi S., Katayama K., Maeda M., et al. PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability. J Gene Med 2005, 7(5):604-612.
115. Maeda M., Kida S., Hojo K., Eto Y., Gaob J.Q., Kurachi S., et al. Design and synthesis of a peptide-PEG transporter tool for carrying adenovirus vector into cells. Bioorg Med Chem Lett 2005, 15(3):621-624.
116. Ogawara K., Rots M.G., Kok R.J., Moorlag H.E., Van Loenen A.M., Meijer D.K., et al. A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo. Hum Gene Ther 2004, 15(5):433-443.
117. Ogawara K., Kuldo J.M., Oosterhuis K., Kroesen B.J., Rots M.G., Trautwein C., et al. Functional inhibition of NF-kappaB signal transduction in alphavbeta3 integrin expressing endothelial cells by using RGD-PEG-modified adenovirus with a mutant IkappaB gene. Arthritis Res Ther 2006, 8(1):R32.
118. Niu G., Xiong Z., Cheng Z., Cai W., Gambhir S.S., Xing L., et al. In vivo bioluminescence tumor imaging of RGD peptide-modified adenoviral vector encoding firefly luciferase reporter gene. Mol Imaging Biol 2007, 9(3):126-134.
119. Stevenson M., Hale A.B., Hale S.J., Green N.K., Black G., Fisher K.D., et al. Incorporation of a laminin-derived peptide (SIKVAV) on polymer-modified adenovirus permits tumor-specific targeting via alpha6-integrins. Cancer Gene Ther 2007, 14(4):335-345.
120. Parker A.L., Fisher K.D., Oupicky D., Read M.L., Nicklin S.A., Baker A.H., et al. Enhanced gene transfer activity of peptide-targeted gene-delivery vectors. J Drug Target 2005, 13(1):39-51.
121. Yao X., Yoshioka Y., Morishige T., Eto Y., Narimatsu S., Kawai Y., et al. Tumor vascular targeted delivery of polymer-conjugated adenovirus vector for cancer gene therapy. Mol Ther 2011, 19(9):1619-1625.
122. Gotoh N. Regulation of growth factor signaling by FRS2 family docking/scaffold adaptor proteins. Cancer Sci 2008, 99(7):1319-1325.
123. Black P.C., Agarwal P.K., Dinney C.P. Targeted therapies in bladder cancer-an update. Urol Oncol 2007, 25(5):433-438.
124. Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer 2001, 8(1):3-9.
125. Alper O., Bergmann-Leitner E.S., Bennett T.A., Hacker N.F., Stromberg K., Stetler-Stevenson W.G. Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. J Natl Cancer Inst 2001, 93(18):1375-1384.
126. Bonsted A., Engesaeter B.O., Hogset A., Maelandsmo G.M., Prasmickaite L., D'Oliveira C., et al. Photochemically enhanced transduction of polymer-complexed adenovirus targeted to the epidermal growth factor receptor. J Gene Med 2006, 8(3):286-297.
127. Morrison J., Briggs S.S., Green N., Fisher K., Subr V., Ulbrich K., et al. Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor. Mol Ther 2008, 16(2):244-251.
128. Park J.W., Mok H., Park T.G. Epidermal growth factor (EGF) receptor targeted delivery of PEGylated adenovirus. Biochem Biophys Res Commun 2008, 366(3):769-774.
129. Bonsted A., Engesaeter B.O., Hogset A., Maelandsmo G.M., Prasmickaite L., Kaalhus O., et al. Transgene expression is increased by photochemically mediated transduction of polycation-complexed adenoviruses. Gene Ther 2004, 11(2):152-160.
130. Berg K., Selbo P.K., Prasmickaite L., Tjelle T.E., Sandvig K., Moan J., et al. Photochemical internalization: a novel technology for delivery of macromolecules into cytosol. Cancer Res 1999, 59(6):1180-1183.
131. Korc M., Friesel R.E. The role of fibroblast growth factors in tumor growth. Curr Cancer Drug Targets 2009, 9(5):639-651.
132. Lanciotti J., Song A., Doukas J., Sosnowski B., Pierce G., Gregory R., et al. Targeting adenoviral vectors using heterofunctional polyethylene glycol FGF2 conjugates. Mol Ther 2003, 8(1):99-107.
133. Green N.K., Morrison J., Hale S., Briggs S.S., Stevenson M., Subr V., et al. Retargeting polymer-coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer. J Gene Med 2008, 10(3):280-289.
134. Rancourt C., Rogers B.E., Sosnowski B.A., Wang M., Piche A., Pierce G.F., et al. Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer. Clin Cancer Res 1998, 4(10):2455-2461.
135. Roghani M., Moscatelli D. Basic fibroblast growth factor is internalized through both receptor-mediated and heparan sulfate-mediated mechanisms. J Biol Chem 1992, 267(31):22156-22162.
136. Plosker G.L., Figgitt D.P. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2003, 63(8):803-843.
137. Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., et al. First-line Herceptin monotherapy in metastatic breast cancer. Oncology 2001, 61(Suppl. 2):37-42.
138. Vecchione L., Orditura M., Ciardiello F., De Vita F. Novel investigational drugs for gastric cancer. Expert Opin Investig Drugs 2009, 18(7):945-955.
139. Bange J., Zwick E., Ullrich A. Molecular targets for breast cancer therapy and prevention. Nat Med 2001, 7(5):548-552.
140. Santin A.D., Bellone S., Roman J.J., McKenney J.K., Pecorelli S. Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. Int J Gynaecol Obstet 2008, 102(2):128-131.
141. Jung Y., Park H.J., Kim P.H., Lee J., Hyung W., Yang J., et al. Retargeting of adenoviral gene delivery via herceptin-PEG-adenovirus conjugates to breast cancer cells. J Control Release 2007, 123(2):164-171.
142. Kim P.H., Sohn J.H., Choi J.W., Jung Y., Kim S.W., Haam S., et al. Active targeting and safety profile of PEG-modified adenovirus conjugated with herceptin. Biomaterials 2011, 32(9):2314-2326.
143. Bokemeyer C., Bondarenko I., Makhson A., Hartmann J.T., Aparicio J., de Braud F., et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009, 27(5):663-671.
144. Goldstein N.I., Prewett M., Zuklys K., Rockwell P., Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995, 1(11):1311-1318.
145. del Carmen M.G., Rizvi I., Chang Y., Moor A.C., Oliva E., Sherwood M., et al. Synergism of epidermal growth factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo. J Natl Cancer Inst 2005, 97(20):1516-1524.
146. Morrison J., Briggs S.S., Green N.K., Thoma C., Fisher K.D., Kehoe S., et al. Cetuximab retargeting of adenovirus via the epidermal growth factor receptor for treatment of intraperitoneal ovarian cancer. Hum Gene Ther 2009, 20(3):239-251.
147. Sato H., Usuda N., Kuroda M., Hashimoto S., Maruta M., Maeda K. Significance of serum concentrations of E-selectin and CA19-9 in the prognosis of colorectal cancer. Jpn J Clin Oncol 2010, 40(11):1073-1080.
148. Dabelsteen E. Cell surface carbohydrates as prognostic markers in human carcinomas. J Pathol 1996, 179(4):358-369.
149. Kannagi R. Carbohydrate-mediated cell adhesion involved in hematogenous metastasis of cancer. Glycoconj J 1997, 14(5):577-584.
150. Bachtarzi H., Stevenson M., Ubr V., Seymour L.W., Fisher K.D. E-selectin is a viable route of infection for polymer-coated adenovirus retargeting in TNF-?-activated human umbilical vein endothelial cells. J Drug Target 2011.
151. Willemsen R.A., Pechar M., Carlisle R.C., Schooten E., Pola R., Thompson A.J., et al. Multi-component polymeric system for tumour cell-specific gene delivery using a universal bungarotoxin linker. Pharm Res 2010, 27(11):2274-2282.
152. Meshkin B., Blum K. Folate nutrigenetics: a convergence of dietary folate metabolism, folic acid supplementation, and folate antagonist pharmacogenetics. Drug Metab Lett 2007, 1(1):55-60.
153. Sirotnak F.M. Obligate genetic expression in tumor cells of a fetal membrane property mediating " folate" transport: biological significance and implications for improved therapy of human cancer. Cancer Res 1985, 45(9):3992-4000.
154. Glynn S.A., Albanes D. Folate and cancer: a review of the literature. Nutr Cancer 1994, 22(2):101-119.
155. Schulz W.A. DNA methylation in urological malignancies (review). Int J Oncol 1998, 13(1):151-167.
156. Ross J.F., Chaudhuri P.K., Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 1994, 73(9):2432-2443.
157. Zhao X.B., Lee R.J. Tumor-selective targeted delivery of genes and antisense oligodeoxyribonucleotides via the folate receptor. Adv Drug Deliv Rev 2004, 56(8):1193-1204.
158. Konda S.D., Aref M., Brechbiel M., Wiener E.C. Development of a tumor-targeting MR contrast agent using the high-affinity folate receptor: work in progress. Invest Radiol 2000, 35(1):50-57.
159. Giaginis C., Zarros A., Alexandrou P., Klijanienko J., Delladetsima I., Theocharis S. Evaluation of coxsackievirus and adenovirus receptor expression in human benign and malignant thyroid lesions. Apmis 2010, 118(3):210-221.
160. Glasgow J.N., Everts M., Curiel D.T. Transductional targeting of adenovirus vectors for gene therapy. Cancer Gene Ther 2006, 13(9):830-844.
161. Nicklin S.A., Wu E., Nemerow G.R., Baker A.H. The influence of adenovirus fiber structure and function on vector development for gene therapy. Mol Ther 2005, 12(3):384-393.
162. Oh I.K., Mok H., Park T.G. Folate immobilized and PEGylated adenovirus for retargeting to tumor cells. Bioconjug Chem 2006, 17(3):721-727.